Today’s top gainers include the company Medivation, Inc. (NASDAQ:MDVN) which is in the industry Biotechnology, gaining -0.34% today. In the last week its performance is 1.21%, and 18.98% for the past quarter. Currently, Medivation, Inc., MDVN has a target price of 64.82, so today’s gain of -0.34% is a significant step towards its target price. The GAP today is therefore 0.22%.
Medivation, Inc. (NASDAQ:MDVN), has a market cap of 10295.75, and is based in USA. Insider ownership is at 1.20%, and institutional ownership is 93.00%.
At the current price of 62.42, it has a dividend yield of *TBA, and its target price is 64.82. This is with a profit margin of 25.40%, and total debt/equity of 0. Medivation, Inc. (NASDAQ:MDVN) has a P/E of 43.8, as well as a forward P/E of 28.52.
With a current EPS of 1.43, and a forecasted EPS growth for next year at 70.50%,Medivation, Inc. (NASDAQ:MDVN) has had a EPS growth for the past five years at 50.90%. For the next five years EPS growth is projected to be 35.15%.
Performance for the year is 15.44%. Since its IPO date on 1/13/1997, the total performance to date is 29.56%.
Volume today for Medivation, Inc. (NASDAQ:MDVN), is 594920, while its average volume is 2760.37. Whilst the total gain today was -0.34%, it did have a day high of -1.47%.
Volatility for this week has been at 1.44%, and 1.88% for the month. The 52-week low for Medivation, Inc., MDVN has been 136.35%, while the 52-week-high has reached -1.47%.
Looking at its return of investments, which is 27.10%, and its return on assets is 21.50%. Medivation, Inc. (NASDAQ:MDVN) has an operating margin of 40.20%. With a sales growth of 41.30% quarter over quarter. Bearing in mind that Medivation, Inc., MDVN is in the sector Healthcare, its long-term debt/equity is 0, and has a current ratio of 4.2 and 4.2 for quick ratio.
So what is the value of Medivation, Inc.? Well its PEG is 1.25, and the P/S is 10.33, along with a P/B of 11.43. Meanwhile it has a p/cash of *TBA.